An Audit Vabysmo vs Ongavia: Who is the Fairest of them all?

1. Chanelle Smith, Wye Valley NHS Trust
2. Sam Jacobs , University of Birmingham
3. Sheeja Thomas, Wye Valley NHS Trust

INTRODUCTION

- Vabysmo (Faricimab) is newer generation intra-vitreal (IVT) injection only approved by NICE in June 2022.
- Its loading dose consists of 4 injections, once every month.



Figure 1 - Vabysmo (faricimab)

- Ongavia (Ranibizumab) is another anti-VEGF treatment which in contrast consists of 3 injections, once every month.
- Intra-vitreal injections have transformed the visual prognosis of various retinal conditions such as age-macular degeneration and diabetic macular oedema.



Figure 2 - Ongavia (ranzibizumab)

AIMS

The aim of our audit was to compare the efficacy of Vabysmo to Ongavia to ensure these treatments deliver the expected outcomes while maintaining a favourable safety profile:

- Reduction in central macular thickness
- Gain in visual acuity (VA) after loading doses

METHODS

- Utilising a retrospective approach, all patients receiving Vabysmo or Ongavia injections at Hereford County Hospital in 2023 were identified.
- Only patients who had completed the loading doses were included.

The following were recorded:

- Patient demographics
- Injection details
- CMT reduction
- VA gain
- Side effects



RESULTS

- Ten patients had Vabysmo including 6 females and 4 males with a mean age of 81.
- Seven patients had Ongavia including 4 females and 3 males with a mean age of 85.
- All patients were treated for age macular degeneration and all ethnicities recorded were Caucasian.
- The mean CMT reduction for patients taking Vabysmo was 34µm ± 27.9 compared with 8µm ± 49.3 with Ongavia.
- The mean number of letters gained with Vabysmo were 6.4 ± 15.4 compared with 2.9 ±8.5 with Ongavia.




Figure 3 - Average CMT reduction. n=10 for Vabysmo, n=7 patients for Ongavia.

Vabysmo was 34µm ± 27.9 compared with 8µm ± 49.3 with Ongavia.




Figure 4 - Average number of letters gained or lost. n=10 for Vabysmo, n=7 patients for Ongavia.

Vabysmo was 6.4 ± 15.4 compared with 2.9 ±8.5 with Ongavia.

CONCLUSION

- Vabysmo showed a ***greater CMT reduction and gain in letters compared*** to Ongavia suggesting greater efficacy at treating AMD.
- Vabysmo is the first licensed treatment to combine anti-VEGF and anti-Ang-2 action, which has shown quicker resolution of fluid and larger interims between follow ups.
- There were few side effects noted for both injections suggesting good patient tolerability.
- It would be useful in further studies to compare its use for treating diabetic macular odema.




*Figure 5- Figure to show the mechanism of **VEGF = vascular endothelial growth** factor and **Ang-2 = angiopoietin-2)**, proteins in the eye that cause blood vessels to grow abnormally, swell, and leak fluid. Vabysmo is the first licensed treatment which combines anti-VEGF and anti-ANg-2 to reduce this process and help to treat wet AMD.*

REFERENCES

1. https://www.medicines.org.uk/emc/product/13741/smpc#gref
2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6014888/
3. https://www.moorfields-private.co.uk/news/news-article/new-intravitreal-treatment-for-wet-amd-and-diabetic-macular-oedema
4. https://www.dgft.nhs.uk/wp-content/uploads/2023/03/Faricimab-Vabysmo-ARMD-v1-r05-2025_Upload-version.pdf
5. https://www.medicines.org.uk/emc/product/13885/smpc#gref
6. https://www.moorfields.nhs.uk/sites/default/files/Ranibizumab_0.pdf
7. https://www.sps.nhs.uk/articles/the-licence-and-supporting-evidence-for-ranibizumab-biosimilar/
8. https://www.vabysmo.com/wamd/learn-about-wamd.html